33446-15-0Relevant academic research and scientific papers
A diastereoselective total synthesis of the sesquiterpene (±)-mutisianthol
Ferraz, Helena M. C.,Aguilar, Andrea M.,Silva Jr., Luiz F.
, p. 5817 - 5821 (2003)
The total synthesis of the phenolic sesquiterpene mutisianthol has been accomplished in 12 steps from the readily available 2-methylanisole. The required trans-1,3-disubstituted indan intermediate was obtained through a diastereoselective thallium(III) me
(+)- And (-)-mutisianthol: First total synthesis, absolute configuration, and antitumor activity
Bianco, Graziela G.,Ferraz, Helena M. C.,Costas, Arinice M.,Costa-Lotufo, Leticia V.,Pessoa, Claudia,De Moraes, Manoel O.,Schreins, Marcus G.,Pfaltz, Andreas,Silva Jr., Luiz F.
supporting information; experimental part, p. 2561 - 2566 (2009/09/25)
The first synthesis of the natural product (+)-mutisianthol was accomplished in 11 steps and in 21% overall yield from 2-methylanisole. The synthesis of its enantiomer was also performed in a similar overall yield. The absolute configuration of the sesquiterpene (+)-mutisianthol was assigned as (15,37?). Key steps in the route are the asymmetric hydrogenation of a nonfunctionalized olefin using chiral iridium catalysts and the ring contraction of 1,2-dihydronaphthalenes using thallium(III) or iodine(III). The target molecules show moderate activity against the human tumor cell lines SF-295, HCT-8, and MDA-MB-435.
Enzymatic resolution of α-tetralols by CALB-catalyzed acetylation
Ferraz, Helena M.C.,Bianco, Graziela G.,Teixeira, Carla C.,Andrade, Leandro H.,Porto, Andre L.M.
, p. 1070 - 1076 (2008/02/08)
A series of homochiral α-tetralols, as well as their respective acetates, has been obtained by esterification of racemic tetralols, using Candida antarctica lipase (CALB-Novozym 435) as the biocatalyst. This enzyme is shown to be highly efficie
AMINO ALCOHOL COMPOUND
-
Page/Page column 57, (2010/11/25)
A pharmaceutical composition is provided that has a low toxicity, demonstrates superior physicochemical properties and pharmacokinetics, and has superior peripheral blood lymphocyte count lowering activity. The pharmaceutical composition contains a compound having general formula (I): (wherein R 1 represents a methyl group or an ethyl group, R 2 represents a methyl group or an ethyl group, and R 3 represents a phenyl group substituted with 1 to 3 substituents selected from the group consisting of a halogen atom, a lower alkyl group, a cycloalkyl group, a lower alkoxy group, a halogeno lower alkyl group, a lower aliphatic acyl group and a cyano group), a pharmacologically acceptable salt thereof or a pharmacologically acceptable ester thereof.
4,5-DIHYDRONAPHTHO [1,2-b] THIOPHENE DERIVATIVE
-
Page/Page column 13, (2010/11/08)
A 4,5-dihydronaphtho[1,2-b]thiophene derivative expressed by the formula: (wherein R1 is a C1 to C10 1-hydroxyalkyl group or a C1 to C10 acyl group, and R2 and R3 separately substitute in the 6-, 7-, 8-, or 9-positions, and are each independently a hydrogen atom, a halogen atom, a C1 to C10 alkyl group, a hydroxy group, a C1 to C10 alkoxy group, a C1 to C5 alkenyloxy group, a C1 to C5 alkynyloxy group, a benzyloxy group, or the like, provided that when R1 is an acyl group and R2 is a hydrogen atom, then R3 is neither a hydrogen atom nor an acetyl group), or a pharmaceutically acceptable salt thereof. This is a novel compound that is effective in reducing triglyceride levels in the liver and reducing blood glucose levels.
Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
-
, (2008/06/13)
Compounds of the formula where the symbols are as defined in the specification, have retinoid agonist, antagonist or negative hormone-like biological activity.
Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
-
, (2008/06/13)
Compounds of the formula where the symbols are as defined in the specification, have retinoid agonist, antagonist or negative hormone-like biological activity.
Identification and synthesis of trinorcadalene phytoalexins formed by hibiscus cannabinus in honour of professor G. H. Neil towers 75th birthday
Bell, Alois A.,Stipanovic, Robert D.,Zhang, Jiuxu,Mace, Marshall E.,Reibenspies, Joseph H.
, p. 431 - 440 (2007/10/03)
Two trinorcadalene phytoalexins, hibiscanal (2,8-dihydroxy-4,7-dimethoxy-6-methyl-1-naph-thaldehyde) and o-hibiscanone (3,8-dimethyl-1,2-naphthoquinone), were isolated and identified from stem stele of kenaf (Hibiscus cannabinus) inoculated with the funga
A novel type of retinoic acid receptor antagonist: Synthesis and structure-activity relationships of heterocyclic ring-containing benzoic acid derivatives
Yoshimura,Nagai,Hibi,Kikuchi,Abe,Hida,Higashi,Yamanaka
, p. 3163 - 3173 (2007/10/02)
A new series of heterocyclic ring-containing benzoic acids was prepared, and the binding affinity and antagonism of its members against all-trans- retinoic acid were evaluated by in vitro assay systems using human promyelocytic leukemia (HL-60) cells. Structure-activity relationships indicated that both an N-substituted pyrrole or pyrazole (1-position) and a hydrophobic region, with these linked by a ring system, were indispensable for effective antagonism. Among the compounds evaluated, optimal antagonism was exhibited by 4-[4,5,7,8,9,10-hexahydro-7,7,10,-10-tetramethyl-1-(3- pyridylmethyl)anthra[1,2-b]pyrrol-3-yl]benzoic acid (31), 4-[4,5,7,8,9,10- hexahydro-7,7,10,10-tetramethyl-1-(3-pyridylmethyl)-5-thiaanthra[1,2- b]pyrrol-3-yl]benzoic acid (40), and 4-[4,5,7,8,9,10-hexahydro-7,7,10,10- tetramethyl-1-(3-pyridylmethyl)anthra[2,1-d]pyrazol-3-yl]benzoic acid (55), all of which possess a 3-pyridylmethyl group at the five-membered ring nitrogen atom.
